These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11583476)

  • 1. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
    Gobburu JV; Tammara V; Lesko L; Jhee SS; Sramek JJ; Cutler NR; Yuan R
    J Clin Pharmacol; 2001 Oct; 41(10):1082-90. PubMed ID: 11583476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
    Polinsky RJ
    Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
    Cutler NR; Polinsky RJ; Sramek JJ; Enz A; Jhee SS; Mancione L; Hourani J; Zolnouni P
    Acta Neurol Scand; 1998 Apr; 97(4):244-50. PubMed ID: 9576639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
    Hossain M; Jhee SS; Shiovitz T; McDonald C; Sedek G; Pommier F; Cutler NR
    Clin Pharmacokinet; 2002; 41(3):225-34. PubMed ID: 11929322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
    Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
    J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
    Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
    Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
    Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
    J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration.
    Tse FL; Laplanche R
    Pharm Res; 1998 Oct; 15(10):1614-20. PubMed ID: 9794506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain.
    Enz A; Gentsch C
    Neuropharmacology; 2004 Sep; 47(3):408-13. PubMed ID: 15275830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease.
    Rompicherla SKL; Arumugam K; Bojja SL; Kumar N; Rao CM
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1737-1755. PubMed ID: 34086100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
    Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
    Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
    Shua-Haim J; Smith J; Picard F; Sedek G; Athalye S; Pommier F; Lefèvre G
    Clin Drug Investig; 2008; 28(6):361-74. PubMed ID: 18479178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.